EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access

Aberrant p53 expression, a stronger risk factor for neoplastic progression in Barrett’s esophagus than confirmed low grade dysplasia: a large multicenter prospective cohort study

Pauline A Zellenrath, Nanda Provoost, Jeliena C M Jansen, Nina van Gerwen, Michael Doukas, Pieter Jan F de Jonge, Arjun D Koch, Judith Honing, Manon C W Spaander, Probar Study Group

Endoscopy · 01.09.2026 · 58 (09) · 937-946

DOI: 10.1055/a-2863-0566 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Endoscopy, erschienen am 01.09.2026. Verfasst von Pauline A Zellenrath und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Adenocarcinoma, Barrett Esophagus, Esophageal Neoplasms, Precancerous Conditions. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Low grade dysplasia (LGD) diagnosed on multiple occasions is considered the strongest risk factor for neoplastic progression in patients with Barrett’s esophagus (BE); however, recent studies have shown that aberrant p53 expression may be a more powerful risk factor for progression. This study aimed to compare the association between aberrant p53 expression versus LGD diagnosed on two or more occasions and neoplastic progression risk.

Methods

Patients with a BE segment length ≥ 2 cm were included in a multicenter prospective cohort. p53 expression was determined by immunohistochemistry staining. Neoplastic progression was defined as development of high grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). Multivariable Cox regression analyses were used to determine the association between selected variables and neoplastic progression risk.

Results

960 patients (median age 62; 73 % men) were included. During a median (interquartile range) follow-up of 6.3 (3.5–11.9) years, 81 patients (8 %) developed HGD/EAC. p53 expression was aberrant in 24 % of patients, and was strongly associated with an increased risk of progression (hazard ratio [HR] 20.0, 95 %CI 10.0–40.0). In contrast, LGD on multiple occasions was not similarly associated (HR 0.84, 95 %CI 0.47–1.53), after adjustment for age, sex, and segment length. Progression-free survival was better in patients with normal versus aberrant p53 expression, regardless of the histopathological diagnosis (P < 0.001).

Conclusions

Aberrant p53 expression is strongly associated with an increased neoplastic progression risk in BE patients, regardless of the histopathological findings. It may therefore be a better parameter than confirmed LGD on multiple occasions to identify patients who might benefit from ablation therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaBarrett EsophagusEsophageal NeoplasmsPrecancerous ConditionsTumor Suppressor Protein p53AgedFemaleHumansMaleMiddle AgedDisease ProgressionImmunohistochemistryProspective StudiesRisk FactorsCohort Studies

Substanzen

TP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Department of Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Zitieren

APA

Zellenrath, P. A., Provoost, N., Jansen, J. C. M., van Gerwen, N., Doukas, M., de Jonge, P. J. F., Koch, A. D., Honing, J., Spaander, M. C. W., & Probar Study Group (2026). Aberrant p53 expression, a stronger risk factor for neoplastic progression in Barrett’s esophagus than confirmed low grade dysplasia: a large multicenter prospective cohort study. Endoscopy, 58(09), 937-946. https://doi.org/10.1055/a-2863-0566

Vancouver

Zellenrath PA, Provoost N, Jansen JCM, van Gerwen N, Doukas M, de Jonge PJF, et al. Aberrant p53 expression, a stronger risk factor for neoplastic progression in Barrett’s esophagus than confirmed low grade dysplasia: a large multicenter prospective cohort study. Endoscopy. 2026;58(09):937-946. doi:10.1055/a-2863-0566

BibTeX
@article{Zellenrath2026,
  author = {Zellenrath, Pauline A and Provoost, Nanda and Jansen, Jeliena C M and van Gerwen, Nina and Doukas, Michael and de Jonge, Pieter Jan F and Koch, Arjun D and Honing, Judith and Spaander, Manon C W and Probar Study Group, Probar Study Group},
  title = {Aberrant p53 expression, a stronger risk factor for neoplastic progression in Barrett’s esophagus than confirmed low grade dysplasia: a large multicenter prospective cohort study},
  journal = {Endoscopy},
  year = {2026},
  volume = {58},
  number = {09},
  pages = {937--946},
  doi = {10.1055/a-2863-0566}
}
Kostenlos starten →